Lakeland Financial Corporation reported strong first-quarter 2026 results, with net income increasing 32% to $26.5 million and diluted EPS rising 33% to $1.04. The company achieved significant organic growth in loans and deposits, alongside an expanded net interest margin. These results reflect a disciplined strategy, strong capital foundation, and continued investment in technology and market presence.

Lakeland Financial Corporation reported record first-quarter net income of $26.5 million, a 32% increase year-over-year, with diluted earnings per share rising 33% to $1.04. The company achieved 9% revenue growth and 5% loan growth, driven by strong net interest margin expansion and increased fee-based revenue. LKFN also increased its common dividend by 4% to $0.52 per share and repurchased 336,853 shares for $19.2 million.

U.S. Energy Corp. (USEG) entered into a 5-year Helium Sales Agreement with an investment-grade industrial gas company. The agreement covers 100% of the contained helium produced at USEG's new purification plant near Oilmont, Montana, up to 1.2 million cubic feet per month. The fixed base price is $285.00 per MCF, with annual adjustments based on CPI-U, and the counterparty handles all downstream costs. This agreement is a key long-term offtake for the company's Big Sky Carbon Hub, with initial sales anticipated in Q1 2027.

GSK plc and its subsidiary TESARO are involved in ongoing litigation with AnaptysBio concerning a license agreement for dostarlimab (Jemperli). AnaptysBio alleges TESARO has not fulfilled certain requirements of the March 2014 agreement and intends to revoke the license. GSK and TESARO firmly deny these allegations, viewing them as entirely without merit, and remain focused on pursuing their claim at trial. Jemperli is currently approved in over 35 countries for certain endometrial cancers and has reported significant growth, with an ambitious clinical trial program underway for additional cancer indications.

NOVONIX Limited filed a Form 6-K with the SEC on April 27, 2026. The filing indicates an application for the quotation of securities, as detailed in Appendix 2A. This is a routine corporate action for listing new shares.

HawkEye 360, Inc. filed an S-1/A for its initial public offering, proposing to offer 16,000,000 shares of common stock at an estimated price range of $24.00 to $26.00 per share. The company, which acquired Innovative Signal Analysis, Inc. in December 2025, reported a funded backlog of $302.7 million and a net income of $2.7 million for the year ended December 31, 2025. It plans to list on the NYSE under "HAWK" and estimates its total addressable market to reach $34 billion by 2030.

SCHMID Group N.V. provided an operational update for Q1 2026, reporting €13.6 million in order intake and €18.2 million in revenues, with an order book of €49 million. Despite a soft first quarter, the company reaffirmed its full-year 2026 guidance, expecting revenues over €100 million and an Adjusted EBITDA margin exceeding 12%. Additionally, the company announced significant capital actions, including the conversion of $12 million in convertible notes into 2,197,898 shares and plans to issue shares to offset €30.75 million in financial liabilities, pending shareholder approval. These actions are expected to strengthen the balance sheet and reduce leverage.

Fulcrum Therapeutics, Inc. announced the appointment of Josh Lehrer, M.D., M.Phil., FACC, as an independent director to its Board of Directors. Dr. Lehrer brings over two decades of clinical development experience, including leadership in the development and approval of Oxbryta for sickle cell disease. His expertise in rare disease drug development is expected to be invaluable as Fulcrum advances its lead program, pociredir, for sickle cell disease.

Rein Therapeutics, Inc. filed an amendment to its Form 10-K, specifically Part III, to include previously omitted information regarding corporate governance and executive compensation. The amendment details the Board of Directors' composition, committee memberships, and corporate governance practices, including policies on director independence, risk management, and insider trading. It also provides the summary compensation table for its Named Executive Officers (NEOs) for fiscal years 2024 and 2025, outlining salaries, bonuses, and option awards.

HawkEye 360, Inc. filed an S-1/A for its initial public offering of 16,000,000 shares of common stock, with an estimated price range of $24.00 to $26.00 per share. The company also reported a funded backlog of $302.7 million and net income of $2.7 million for the year ended December 31, 2025. This follows the acquisition of Innovative Signal Analysis, Inc. in December 2025, enhancing its signal processing capabilities and market reach.

KE Holdings Inc. filed a Form 6-K with the SEC, submitting five Next Day Disclosure Returns. These returns cover the period from April 20, 2026, to April 24, 2026, and are routine disclosures often related to changes in share capital or transactions.

Rein Therapeutics, Inc. filed an amended 10-K to include previously omitted information regarding its corporate governance, board of directors, executive officers, and executive compensation. The amendment details the composition of the board and its committees, the roles and compensation of named executive officers for 2024 and 2025, and various corporate governance policies. New certifications from the principal executive and financial officers were also filed.

Eton Pharmaceuticals, Inc. announced the dosing of the first patient in a pilot clinical study for ET-700, its proprietary extended-release zinc acetate formulation for Wilson disease. This study aims to assess the efficacy of a simpler dosing regimen using 64Cu PET imaging to reduce intestinal copper absorption. Topline results are anticipated in the second half of 2026, with a pivotal study planned for early 2027 if the pilot is successful. The company believes ET-700 could achieve over $100 million in peak annual sales in the U.S.

Easterly Government Properties, Inc. reported strong first quarter 2026 results with Core FFO of $0.77 per share and net income of $0.03 per share. The company raised the lower end of its full-year 2026 Core FFO guidance to a range of $3.06 - $3.12 per share. Strategic activities included the acquisition of a 297,713 square foot campus in Virginia and a $7.0 million mezzanine construction loan, alongside a declared quarterly dividend of $0.45 per share.

Smith+Nephew (SNN) announced it will host an expert surgeon insights event for investors and financial analysts in London on June 9, 2026. The event will feature renowned surgeons from leading US healthcare institutions discussing key innovation platforms expected to drive the next phase of growth for Smith+Nephew's RISE strategy. These platforms include products across Sports Medicine, Advanced Wound Management, and Orthopaedics. The event will be hosted by CEO Deepak Nath and CFO John Rogers, with Q&A sessions and product demonstrations.